These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 15492322)

  • 1. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.
    Asselbergs FW; Diercks GF; Hillege HL; van Boven AJ; Janssen WM; Voors AA; de Zeeuw D; de Jong PE; van Veldhuisen DJ; van Gilst WH;
    Circulation; 2004 Nov; 110(18):2809-16. PubMed ID: 15492322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
    Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
    Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria:Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT).
    Brouwers FP; Asselbergs FW; Hillege HL; de Boer RA; Gansevoort RT; van Veldhuisen DJ; van Gilst WH
    Am Heart J; 2011 Jun; 161(6):1171-8. PubMed ID: 21641365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial.
    Geluk CA; Asselbergs FW; Hillege HL; Bakker SJ; de Jong PE; Zijlstra F; van Gilst WH
    Eur Heart J; 2005 Jul; 26(13):1314-20. PubMed ID: 15820998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study.
    Atthobari J; Brantsma AH; Gansevoort RT; Visser ST; Asselbergs FW; van Gilst WH; de Jong PE; de Jong-van den Berg LT;
    Nephrol Dial Transplant; 2006 Nov; 21(11):3106-14. PubMed ID: 16720593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]).
    Diercks GF; Janssen WM; van Boven AJ; Bak AA; de Jong PE; Crijns HJ; van Gilst WH
    Am J Cardiol; 2000 Sep; 86(6):635-8. PubMed ID: 10980214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency.
    Tong PC; Ko GT; Chan WB; Ma RC; So WY; Lo MK; Lee KF; Ozaki R; Chow CC; Cockram CS; Chan JC
    Diabetes Obes Metab; 2006 May; 8(3):342-7. PubMed ID: 16634995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria.
    Asselbergs FW; van Roon AM; Hillege HL; de Jong PE; Gans RO; Smit AJ; van Gilst WH;
    Stroke; 2005 Mar; 36(3):649-53. PubMed ID: 15692120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
    Tonelli M; Isles C; Curhan GC; Tonkin A; Pfeffer MA; Shepherd J; Sacks FM; Furberg C; Cobbe SM; Simes J; Craven T; West M
    Circulation; 2004 Sep; 110(12):1557-63. PubMed ID: 15364796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects.
    Asselbergs FW; van der Harst P; van Roon AM; Hillege HL; de Jong PE; Gans ROB; Smit AJ; van Gilst WH
    Atherosclerosis; 2008 Jan; 196(1):349-355. PubMed ID: 17141245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of angiotensin-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondiabetic patients.
    van de Wal RM; Gansevoort RT; van der Harst P; Boomsma F; Thijs Plokker HW; van Veldhuisen DJ; de Jong PE; van Gilst WH; Voors AA
    Hypertension; 2006 Nov; 48(5):870-6. PubMed ID: 17000930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects.
    van de Wal RM; van der Harst P; Gerritsen WB; van der Horst F; Plokker TH; Gansevoort RT; van Gilst WH; Voors AA
    J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):177-80. PubMed ID: 18205096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of a low-dose regimen of fosinopril on elevated urinary albumin excretion in normotensive type 1 diabetic patients.
    Carella MJ; Gossain VV; Jones J
    J Med; 1999; 30(5-6):305-20. PubMed ID: 10851564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Packard CJ; Ford I; Robertson M; Shepherd J; Blauw GJ; Murphy MB; Bollen EL; Buckley BM; Cobbe SM; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG;
    Circulation; 2005 Nov; 112(20):3058-65. PubMed ID: 16275871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria.
    van der Harst P; Asselbergs FW; Hillege HL; Voors AA; van Veldhuisen DJ; van Gilst WH;
    Am J Cardiol; 2008 Jul; 102(2):223-5. PubMed ID: 18602526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pravastatin in people with diabetes and chronic kidney disease.
    Tonelli M; Keech A; Shepherd J; Sacks F; Tonkin A; Packard C; Pfeffer M; Simes J; Isles C; Furberg C; West M; Craven T; Curhan G
    J Am Soc Nephrol; 2005 Dec; 16(12):3748-54. PubMed ID: 16251235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion.
    Brantsma AH; Bakker SJ; Hillege HL; de Zeeuw D; de Jong PE; Gansevoort RT;
    Nephrol Dial Transplant; 2008 Dec; 23(12):3851-8. PubMed ID: 18641082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Urinary albumin excretion in non-insulin-dependent diabetic patients. Effects of an angiotensin-converting enzyme inhibitor].
    Durruty P; Tapia JC; Ugarte C; Pérez E; Krause P; Soto N; García de los Ríos M
    Rev Med Chil; 1996 Sep; 124(9):1036-44. PubMed ID: 9197016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pravastatin on blood pressure in people with cardiovascular disease.
    Tonelli M; Sacks F; Pfeffer M; Lopez-Jimenez F; Jhangri GS; Curhan G
    J Hum Hypertens; 2006 Aug; 20(8):560-5. PubMed ID: 16625234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.